Today: 14 May 2026
Browse Category

Pharmaceuticals 7 January 2026 - 9 January 2026

AbbVie stock slips on $1.3B charge, deal-rumor denial — what’s next for ABBV

AbbVie stock slips on $1.3B charge, deal-rumor denial — what’s next for ABBV

AbbVie shares fell 0.8% to $222.35 after the company cut its 2025 profit outlook and denied takeover talks with Revolution Medicines. AbbVie now expects fourth-quarter adjusted EPS of $2.61–$2.65, down from $3.32–$3.36, citing a $1.3 billion pre-tax acquired R&D expense. Wolfe Research downgraded the stock to “Peer Perform.” AbbVie said results for the quarter ended Dec. 31 are not yet final.
9 January 2026
··
Amazon Pharmacy adds Wegovy pill at $149 cash price, putting Novo Nordisk’s NVO stock back in play

Amazon Pharmacy adds Wegovy pill at $149 cash price, putting Novo Nordisk’s NVO stock back in play

Amazon Pharmacy will offer Novo Nordisk’s Wegovy weight-loss pill through insurance and cash-pay, with uninsured customers paying from $149 a month and some insured paying $25. The pill, approved by the FDA in December, will be added to Amazon’s kiosks and is also available at CVS, Costco, and via telehealth. Novo’s U.S. shares rose about 5% to $60.19 Friday morning. Analysts remain split on Novo’s 2026 outlook.
9 January 2026
···
Amazon stock dips as Amazon Pharmacy adds Novo Nordisk’s Wegovy pill, with $25 insured pricing

Amazon stock dips as Amazon Pharmacy adds Novo Nordisk’s Wegovy pill, with $25 insured pricing

Amazon Pharmacy began offering Novo Nordisk’s Wegovy pill nationwide, with insured customers paying as little as $25 per month and uninsured starting at $149. The oral weight-loss drug, approved by U.S. regulators in December, is available for delivery in all 50 states. Amazon shares fell 0.7% to $244.58 in early trading. Broader markets were little changed.
9 January 2026
···
Novo Nordisk (NVO) stock rises premarket as Canada platform touts India-sourced Ozempic

Novo Nordisk (NVO) stock rises premarket as Canada platform touts India-sourced Ozempic

Novo Nordisk’s U.S. shares rose 1.4% in premarket trading after the company denied any relationship with SaveRxCanada.to, which claims to sell India-sourced Ozempic to U.S. patients at $280 per pen. Novo said it has not supplied Ozempic to the platform. The dispute comes as drug pricing faces renewed political scrutiny and ahead of the J.P. Morgan Healthcare Conference.
9 January 2026
···
GSK stock slips in London as hepatitis B drug details awaited; Feb 4 results loom

GSK stock slips in London as hepatitis B drug details awaited; Feb 4 results loom

GSK shares slipped 0.6% to 1,879.5p in London by 10:50 GMT as investors awaited detailed data from its phase III hepatitis B drug trial. Analysts pressed for cure rate and durability figures after GSK withheld specifics. A royalty dispute over cancer drug Jemperli is pending in U.S. court, with a trial set for July 2026. Investors are watching for updates at the Jan. 13 J.P. Morgan conference and Feb. 4 results.
9 January 2026
···
AbbVie stock slides on $1.3 billion charge and outlook cut as deal chatter swirls

AbbVie stock slides on $1.3 billion charge and outlook cut as deal chatter swirls

AbbVie shares fell 4% to $224.13 in after-hours trading Thursday after the company cut its 2025 adjusted profit forecast and disclosed a $1.3 billion acquired R&D charge. The company lowered its full-year 2025 adjusted EPS outlook to $9.90–$9.94 from $10.61–$10.65. AbbVie denied takeover talks with Revolution Medicines. Investors await the company’s Feb. 4 earnings report for further guidance.
9 January 2026
···
Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

Merck shares rose 1.5% to $110.20 after Wolfe Research upgraded the stock and set a $135 price target. Merck completed its $221.50-per-share tender offer for Cidara and flagged a $9 billion R&D charge for 2026. Investors watched fallout from a U.S. shift to a single-dose HPV vaccine recommendation ahead of Merck’s Feb. 3 results.
8 January 2026
····
Pfizer stock price today: PFE ticks up after 340B court block as drug-pricing scrutiny returns

Pfizer stock price today: PFE ticks up after 340B court block as drug-pricing scrutiny returns

Pfizer shares rose 0.3% to $25.36 after a U.S. appeals court blocked a Trump-era pilot that would have changed drug payments for safety-net hospitals. The ruling affects drugs like Eliquis, co-marketed by Pfizer and Bristol Myers Squibb. Investors await Pfizer CEO Albert Bourla’s update at the J.P. Morgan Healthcare Conference on Jan. 12. Pfizer reports earnings Feb. 3, with COVID sales and patent losses in focus.
8 January 2026
··
Omeros stock rises in premarket after $36,000-a-vial Yartemlea price is set

Omeros stock rises in premarket after $36,000-a-vial Yartemlea price is set

Omeros Corp shares rose about 4% to $14.09 premarket after setting a $36,000 price for each vial of newly approved Yartemlea, used to treat TA-TMA in transplant patients. The company began its U.S. launch Jan. 2 and reported $171.5 million in cash at year-end. Shares jumped 6.6% in after-hours trading Wednesday. Analysts raised price targets following the announcement.
8 January 2026
··
AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down

AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down

AbbVie shares fell 1.6% to $229.64 premarket after the company denied talks to acquire Revolution Medicines and cut its 2025 profit forecast. Revolution stock dropped 11.5% following AbbVie’s statement. AbbVie now expects 2025 adjusted EPS of $9.90 to $9.94, down from its previous outlook, citing a $1.3 billion acquired IPR&D charge. Earnings are due Feb. 4.
8 January 2026
···
Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck shares slipped 0.2% in after-hours trading after U.S. health officials cut HPV vaccine guidance to one dose, raising concerns over Gardasil sales. Analysts warned the change could reduce 2026 Gardasil revenue by up to $630 million. Merck also completed its $9.2 billion Cidara acquisition and set Feb. 3 for quarterly results.
8 January 2026
····
AbbVie stock slips after hours after denying Revolution Medicines talks, trims 2025 profit view

AbbVie stock slips after hours after denying Revolution Medicines talks, trims 2025 profit view

AbbVie shares fell 1% to $231.11 in after-hours trading after the company denied reports of takeover talks with Revolution Medicines. A new SEC filing flagged a $1.3 billion fourth-quarter charge, prompting AbbVie to cut its 2025 adjusted earnings forecast to $9.90–$9.94 per share from $10.61–$10.65. Revolution shares dropped 11.5% late.
8 January 2026
····
Eli Lilly stock jumps after $1.2B Ventyx buy as obesity-pill bets come into focus

Eli Lilly stock jumps after $1.2B Ventyx buy as obesity-pill bets come into focus

Eli Lilly shares rose 4.1% to $1,108.09 after the company agreed to acquire Ventyx Biosciences for $1.2 billion in cash. Ventyx holders will receive $14 per share, a 62% premium to its 30-day VWAP. The deal is expected to close in the first half of 2026, pending regulatory and shareholder approval. Lilly also announced a multi-year obesity drug partnership with Nimbus Therapeutics.
7 January 2026
···
Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck shares slipped 0.3% to $108.59 after it completed its tender offer for Cidara Therapeutics and expects to finalize the $9.2 billion acquisition later Wednesday. The deal will add about $9 billion to 2026 R&D expenses and reduce earnings per share by 30 cents in the first year. Merck also began a Phase 3 lung-cancer trial of calderasib with Keytruda QLEX. U.S. officials updated HPV and rotavirus vaccine guidance this week.
7 January 2026
·····
1 … 17 18 19 20 21 … 40

Stock Market Today

  • ICG Enterprise Trust buys back 125,000 shares at 1390p each
    May 14, 2026, 2:55 AM EDT. ICG Enterprise Trust Plc repurchased 125,000 of its own shares on 13 May 2026 at an average price of 1390 pence per share. These shares will be held as treasury shares, increasing total treasury holdings to 2,485,221. The total shares in issue, excluding treasury shares, now stand at 61,068,971. This buyback was executed under authority granted at the June 2025 Annual General Meeting, which allows repurchases up to 14.99% of ordinary shares. The company, using Numis Securities Limited as broker, intends to hold these shares in treasury. No premium above net asset value was paid, adhering to regulatory and shareholder guidelines.

Latest articles

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 14.05.2026

14 May 2026
LIVEMarkets rolling coverageStarted: May 14, 2026, 12:00 AM EDTUpdated: May 14, 2026, 2:55 AM EDT ICG Enterprise Trust buys back 125,000 shares at 1390p each May 14, 2026, 2:55 AM EDT. ICG Enterprise Trust Plc repurchased 125,000 of its own shares on 13 May 2026 at an average price of 1390 pence per share. These shares will be held as treasury shares, increasing total treasury holdings to 2,485,221. The total shares in issue, excluding treasury shares, now stand at 61,068,971. This buyback was executed under authority granted at the June 2025 Annual General Meeting, which allows repurchases up to 14.99%
Enovix Stock Drops After Q1 Beat as Smartphone Battery Tests Stay Unfinished

Enovix Stock Drops After Q1 Beat as Smartphone Battery Tests Stay Unfinished

14 May 2026
Enovix shares dropped 12.9% to $6.35 after hours Wednesday despite beating first-quarter revenue and adjusted-loss estimates. The decline followed news that smartphone battery qualification remains unfinished, with the company passing 72 of 75 customer tests. Revenue rose 49% to $7.6 million. Enovix cited progress in defense, industrial, and smart-eyewear sales.
Lightwave Logic Stock Jumps as AI-Photonics Bet Heads for a 2027 Production Test

Lightwave Logic Stock Jumps as AI-Photonics Bet Heads for a 2027 Production Test

14 May 2026
Lightwave Logic reported Q1 revenue up 27% to $29,000 and a net loss widening to $6.3 million. Shares rose 14% after the company said it is negotiating a supply and licensing deal for high-volume production in 2027. Four Fortune 500 customers are now in Stage 3 prototyping. Cash and equivalents totaled about $100 million as of May 11.
Go toTop